![]() |
市場調查報告書
商品編碼
1949638
聚合酵素連鎖反應熱迴圈儀市場 - 全球產業規模、佔有率、趨勢、機會和預測:按類型、產品類型、應用、最終用戶、地區和競爭格局分類,2021-2031年Thermal Cyclers Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Type, By Product Type, By Application, By End User, By Region & Competition, 2021-2031F |
||||||
全球聚合酵素連鎖反應熱迴圈儀市場預計將從 2025 年的 14.2 億美元成長到 2031 年的 23.1 億美元,複合年成長率達到 8.45%。
這些設備是專門用於實驗室的儀器,透過聚合酵素鏈鎖反應(PCR) 方法擴增特定的 DNA 片段。 PCR 的工作原理是將樣本暴露於精確的溫度變化。市場成長的主要驅動力是遺傳性和感染疾病率的上升,這顯著增加了對精準分子診斷的需求,以便及時治療。此外,基因組分析在法醫學和個人化醫療領域的日益普及,也持續增強了學術和臨床研究領域對這些儀器的迫切需求。
| 市場概覽 | |
|---|---|
| 預測期 | 2027-2031 |
| 市場規模:2025年 | 14.2億美元 |
| 市場規模:2031年 | 23.1億美元 |
| 複合年成長率:2026-2031年 | 8.45% |
| 成長最快的細分市場 | 測試台地類型 |
| 最大的市場 | 北美洲 |
然而,先進設備的高昂成本以及開發中國家檢查室基礎設施的匱乏是市場擴張的主要障礙。這種可近性差距限制了分子診斷技術在最需要的地方的應用。例如,根據世界衛生組織(世衛組織)的數據,到2024年,在前一年全球新確診的820萬結核病患者中,只有48%的人接受了世衛組織推薦的快速分子檢測作為初始診斷方法。
感染疾病和遺傳性疾病的增加是全球聚合酵素連鎖反應熱迴圈儀市場的主要驅動力,迫使臨床檢查室擴展其聚合酵素鏈鎖反應(PCR) 能力。正如美國癌症協會於 2024 年 1 月發布的《2024 年癌症事實與數據》報告所述,美國新增癌症病例數預計將首次超過 200 萬例,達到 2,001,140 例。為了滿足這項需求,強大的腫瘤學工作流程基因組分析工具至關重要。此外,常規病原體監測也維持了較高的設備運轉率。根據美國疾病管制與預防中心 (CDC) 於 2024 年 10 月發布的《2023-2024 年流感季概要》,美國臨床檢查室將檢測 3,887,522 份流感檢體,這表明分子診斷對這些儀器的依賴程度很高。
此外,公共和私人對基因組研究投入的增加正顯著加速市場發展。製藥公司正大力投資基礎設施以支援藥物研發,從而促進了先進擴增設備的引入,而這些設備對於生物製藥開發和品管至關重要。例如,Astra Zeneca在2024年5月的新聞稿中宣布,將在其位於新加坡、耗資15億美元的抗體藥物複合體)生產基地安裝先進的實驗室系統。此類大規模的工業投資表明,對生命科學研發的資金注入如何直接刺激了對現代醫學所需溫度循環設備的潛在需求。
先進設備的高昂成本以及發展中地區實驗室基礎設施的匱乏,嚴重阻礙了全球聚合酵素連鎖反應熱迴圈儀市場的成長。聚合酵素連鎖反應熱迴圈儀不僅需要大量的資金投入用於購買設備,還需要維持穩定的運作環境,包括無菌設施、溫控系統和穩定的電力供應。在許多資源匱乏的地區,由於缺乏這些基礎設施,部署靈敏的分子診斷工具變得不切實際。因此,製造商難以開拓這個龐大的潛在市場,銷售主要侷限於資金雄厚的都市區,導致全球市場普及率停滯不前。
經濟和基礎設施的差距限制了分子診斷的潛在市場,迫使其依賴外部援助而非國內自主採購。這種依賴捐助資金來克服成本障礙的做法表明,該地區的分子診斷市場尚未實現自我維持。據全球基金稱,該組織在2024年專門投資了2.94億美元,用於加強疾病檢測的檢查室和診斷能力。這一數字凸顯出,如果沒有此類有針對性的財政支持,資金和基礎設施方面的障礙仍然過高,難以在發展中市場實現聚合酵素連鎖反應熱迴圈儀的廣泛、永續應用。
數位PCR (dPCR) 技術的廣泛應用正在迅速改變全球聚合酵素連鎖反應熱迴圈儀市場,其無需標準曲線即可實現絕對定量。這項功能在液態生物檢體和腫瘤學領域至關重要,因為這些領域需要精確檢測低表達標靶和罕見等位基因。與傳統定量PCR不同,數位平台將樣本分割成數千個獨立的反應,從而在複雜的診斷流程中提供更高的靈敏度和重複性。為了佐證這一趨勢,凱傑公司在2025年1月的新聞稿中宣布,其QIAcuity數位PCR儀的市場需求依然強勁,截至2024年底累計安裝量已超過2700台。
第二個主要趨勢是用於照護現場的攜帶式和行動裝置的普及,這使得分子檢測從中心檢查室轉移到更靠近患者的場所。製造商正在加速開發緊湊型聚合酵素連鎖反應熱迴圈儀,以便在偏遠地區、診所和急診室提供實驗室等級的精確度。這種轉變滿足了對即時結果的需求,並顯著縮短了症狀檢測和感染疾病控制的周轉時間。反映這一快速成長的是,bioMérieux 在其 2025 年 10 月發布的“2025 年第三季度業務回顧”中報告稱,SPOTFIRE照護現場方案的累計安裝數量已達到 5,500 套。這上年度實現了顯著成長。
The Global Thermal Cyclers Market is projected to expand from USD 1.42 Billion in 2025 to USD 2.31 Billion by 2031, achieving a compound annual growth rate (CAGR) of 8.45%. These devices are specialized laboratory tools used to amplify specific DNA segments via the Polymerase Chain Reaction (PCR) method by exposing samples to exact temperature variations. The market's growth is largely driven by the rising incidence of genetic disorders and infectious diseases, which creates a critical need for precise molecular diagnostics to facilitate timely treatment. Additionally, the broader use of genomic analysis in forensic science and personalized medicine continues to strengthen the essential demand for these instruments within academic and clinical research settings.
| Market Overview | |
|---|---|
| Forecast Period | 2027-2031 |
| Market Size 2025 | USD 1.42 Billion |
| Market Size 2031 | USD 2.31 Billion |
| CAGR 2026-2031 | 8.45% |
| Fastest Growing Segment | Test Mesa Type |
| Largest Market | North America |
Conversely, the substantial expense of advanced equipment and the absence of adequate laboratory infrastructure in developing nations present major obstacles to widespread market growth. This gap in accessibility restricts the use of molecular diagnostics in regions where they are frequently most needed. For instance, data from the World Health Organization reveals that in 2024, only 48% of the 8.2 million people newly diagnosed with tuberculosis globally during the previous year received a WHO-recommended rapid molecular test as their initial diagnostic method.
Market Driver
The rising burden of infectious diseases and genetic disorders acts as a major catalyst for the Global Thermal Cyclers Market, compelling clinical laboratories to enhance their polymerase chain reaction (PCR) capabilities. As noted by the American Cancer Society in their "Cancer Facts & Figures 2024" report from January 2024, new cancer cases in the United States were expected to exceed 2 million for the first time, reaching 2,001,140, a volume that necessitates robust genomic profiling tools for oncology workflows. Furthermore, routine pathogen surveillance keeps equipment utilization high; according to the Centers for Disease Control and Prevention's "Influenza Season Summary 2023-2024" from October 2024, U.S. clinical laboratories tested 3,887,522 influenza specimens, underscoring the critical reliance on these devices for molecular diagnostics.
Additionally, increased public and private funding for genomic research significantly accelerates market momentum. Pharmaceutical companies are investing heavily in infrastructure to support drug discovery, driving the acquisition of advanced amplification devices essential for biopharmaceutical development and quality control. For example, AstraZeneca announced in a May 2024 press release regarding a new USD 1.5 billion antibody-drug conjugate manufacturing facility in Singapore that it is integrating advanced laboratory systems. Such major industrial commitments illustrate how financial injections into life sciences R&D directly stimulate the fundamental demand for the temperature cycling equipment required in modern medicine.
Market Challenge
The substantial cost of advanced instrumentation and the shortage of robust laboratory infrastructure in developing regions significantly hinder the growth of the Global Thermal Cyclers Market. Thermal cyclers demand heavy capital investment, not only for purchasing the devices but also for maintaining a stable operational environment, which requires sterile facilities, climate control, and reliable electricity. In many low-resource settings, these foundational elements are missing, making the deployment of sensitive molecular diagnostic tools impractical. Consequently, manufacturers struggle to penetrate these large potential markets, limiting sales primarily to well-funded urban centers and capping the global adoption rate.
This economic and infrastructural disparity restricts the addressable market for molecular diagnostics, necessitating reliance on external aid rather than organic national procurement. The dependence on donor funding to surmount these cost barriers suggests that the market is not yet self-sustaining in these regions. According to The Global Fund, the organization invested USD 294 million in 2024 specifically to strengthen laboratory and diagnostic capacities for disease detection. This figure highlights that without such targeted financial support, the financial and infrastructural hurdles remain too high to allow for the widespread autonomous adoption of thermal cyclers in developing markets.
Market Trends
The widespread uptake of Digital PCR (dPCR) technology is rapidly reshaping the Global Thermal Cyclers Market by providing absolute quantification without the need for standard curves. This capability is vital in liquid biopsy and oncology applications where the precise detection of low-abundance targets and rare alleles is required. Unlike traditional quantitative PCR, digital platforms partition samples into thousands of individual reactions, offering superior sensitivity and reproducibility for complex diagnostic workflows. Highlighting this trend, Qiagen noted in a January 2025 press release that the adoption of its QIAcuity digital PCR instrument remained robust, achieving over 2,700 cumulative placements by the end of 2024.
A second major trend is the proliferation of handheld and portable devices for point-of-care use, which decentralizes molecular testing from core laboratories to near-patient environments. Manufacturers are increasingly developing compact thermal cyclers that deliver laboratory-grade accuracy in remote field locations, physician offices, and emergency rooms. This shift meets the demand for immediate results, significantly reducing turnaround times for syndromic testing and infectious disease management. Reflecting this surge, BioMerieux reported in its "Third-Quarter 2025 Business Review" from October 2025 that its SPOTFIRE point-of-care solution had reached a total installed base of 5,500 instruments, marking a significant expansion from the previous year.
Report Scope
In this report, the Global Thermal Cyclers Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
Company Profiles: Detailed analysis of the major companies present in the Global Thermal Cyclers Market.
Global Thermal Cyclers Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report: